QuidelOrtho Corp. Stock
€18.50
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| QuidelOrtho Corp. | -19.170% | -23.554% | -27.165% | -50.535% | -55.952% | -79.670% | -92.292% |
| Veeva Systems A | -1.950% | 2.271% | -1.523% | 25.099% | 24.114% | 50.639% | -0.040% |
| Thermo Fisher Scientific Inc. | -1.800% | 1.891% | 5.521% | -5.984% | -1.832% | -1.537% | 10.356% |
| Waters Corp. | -0.710% | 8.286% | 14.862% | -10.744% | -9.589% | 6.917% | 73.784% |
Comments
News
QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a
QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine
QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and



